Safety and dose-ranging study of the effects of SCH 527123 in subjects with moderate to severe COPD.
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Navarixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 16 Sep 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-004287-23).